192 - References

References

Schizophrenia and related psychoses CHAPTER 1 References

1. Suzuki Y, et al. Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-­generation antipsychotics. Schizophr Res 2013; 145:116–119.
2. Tsuboi T, et al. Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: analysis of the CATIE data. Prog Neuropsychopharmacol Biol Psychiatry 2013; 45:178–182.
3. Young RM, et al. Prolactin levels in antipsychotic treatment of patients with schizophrenia carrying the DRD2*A1 allele. Br J Psychiatry 2004; 185:147–151.
4. Haddad PM, et  al. Antipsychotic-­induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64:2291–2314.
5. Holt RI, et  al. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol (Oxf) 2011; 74:141–147.
6. Leucht S, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-­treatments meta-­analysis. Lancet 2013; 382:951–962.
7. Peuskens J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28:421–453.
8. Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol 2013; 9:193–206.
9. Marder SR, et  al. Brexpiprazole in patients with schizophrenia: overview of short-­ and long-­term phase 3 controlled studies. Acta Neuropsychiatr 2017; 29:278–290.
10. Vanover KE, et al. Dopamine D(2) receptor occupancy of lumateperone (ITI-­007): a positron emission tomography study in patients with schizophrenia. Neuropsychopharmacology 2019; 44:598–605.
11. Yunusa I, et al. Pimavanserin: a novel antipsychotic with potentials to address an unmet need of older adults with dementia-­related psychosis. Front Pharmacol 2020; 11:87.
12. Correll CU, et al. Safety and tolerability of KarXT (xanomeline-­trospium) in a phase 2, randomized, double-­blind, placebo-­controlled study in patients with schizophrenia. Schizophrenia (Heidelb) 2022; 8:109.
13. Kaneda Y. The impact of prolactin elevation with antipsychotic medications on subjective quality of life in patients with schizophrenia. Clin Neuropharmacol 2003; 26:182–184.
14. Smith S, et al. The effects of antipsychotic-­induced hyperprolactinaemia on the hypothalamic-­pituitary-­gonadal axis. J Clin Psychopharmacol 2002; 22:109–114.
15. De Hert M, et al. Second-­generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review. Expert Opin Drug Saf 2014; 13:605–624.
16. Baldwin D, et al. Sexual side-­effects of antidepressant and antipsychotic drugs. Adv Psychiatr Treat 2003; 9:202–210.
17. Wieck A, et  al. Antipsychotic-­induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003; 182:199–204.
18. Ali JA, et  al. Delusions of pregnancy associated with increased prolactin concentrations produced by antipsychotic treatment. Int J Neuropsychopharmacol 2003; 6:111–115.
19. De Hert M, et al. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review. Expert Opin Drug Saf 2016; 15:809–823.
20. Tseng PT, et al. Bone mineral density in schizophrenia: an update of current meta-­analysis and literature review under guideline of PRISMA. Medicine (Baltimore) 2015; 94:e1967.
21. De Hert M, et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand 2016; 133:5–22.
22. Holt RI. Medical causes and consequences of hyperprolactinaemia: a context for psychiatrists. J Psychopharmacol 2008; 22:28–37.
23. Melmed S, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273–288.
24. Montejo AL, et al. Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. Front Neuroendocrinol 2017; 45:25–34.
25. Sá Esteves P, et al. Low doses of adjunctive aripiprazole as treatment for antipsychotic-­induced hyperprolactinemia: a literature review. Eur Psychiatry 2015; 30 Suppl 1:393.
26. Yasui-­Furukori N, et al. Dose-­dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010; 30:596–599.
27. Meaney AM, et al. Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 2007; 93:136–143.
28. Hamner MB, et al. Hyperprolactinaemia in antipsychotic-­treated patients: guidelines for avoidance and management. CNS Drugs 1998; 10:209–222.
29. Duncan D, et al. Treatment of psychotropic-­induced hyperprolactinaemia. Psychiatr Bull 1995; 19:755–757.
30. Cavallaro R, et al. Cabergoline treatment of risperidone-­induced hyperprolactinemia: a pilot study. J Clin Psychiatry 2004; 65:187–190.
31. Zhuo C, et al. Safety and efficacy of high-­dose vitamin B6 as an adjunctive treatment for antipsychotic-­induced hyperprolactinemia in male patients with treatment-­resistant schizophrenia. Front Psychiatry 2021; 12:681418.
32. Yuan HN, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone-­induced hyperprolactinemia in patients with schizophrenia. J Clin Psychopharmacol 2008; 28:264–370.

194 The Maudsley® Prescribing Guidelines in Psychiatry CHAPTER 1 33. Man SC, et al. Peony–glycyrrhiza decoction for antipsychotic-­related hyperprolactinemia in women with schizophrenia: a randomized controlled trial. J Clin Psychopharmacol 2016; 36:572–579. 34. Krysiak R, et al. The effect of metformin on prolactin levels in patients with drug-­induced hyperprolactinemia. Eur J Intern Med 2016; 30:94–98. 35. Lu Z, et al. Pharmacological treatment strategies for antipsychotic-­induced hyperprolactinemia: a systematic review and network meta-­ analysis. Transl Psychiatry 2022; 12:267. 36. Zhang L, et al. Efficacy and safety of adjunctive aripiprazole, metformin, and paeoniae-­glycyrrhiza decoction for antipsychotic-­induced hyperprolactinemia: a network meta-­analysis of randomized controlled trials. Front Psychiatry 2021; 12:728204. 37. Jiang Q, et al. Treatment of antipsychotic-­induced hyperprolactinemia: an umbrella review of systematic reviews and meta-­analyses. Front Psychiatry 2024; 15:1337274. 38. Walters J, et  al. Clinical questions and uncertainty: prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol 2008; 22:82–89. 39. Chen CK, et al. Differential add-­on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:1495–1499.